USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HUMACYTE, INC.
Address:
PO BOX 12695
RESEARCH TRIANGLE PARK, NC 27709-
Phone:
N/A
URL:
N/A
EIN:
184166129
DUNS:
557190449
Number of Employees:
30
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $236,549.00 1
SBIR Phase II $4,137,321.00 2

Award List:

Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$236,549.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Engineered tissues are revolutionizing disease therapy in many areas of medicine. It is estimated that the total market size for all types of tissue engineered therapies was 1.5 billion in 2008. But for many t ypes of engineered tissues, including… More

Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,189,820.00
Agency:
HHS
Principal Investigator:
Shannon L. Dahl – 919-597-6625
Abstract:
DESCRIPTION (provided by applicant): This Phase II SBIR application is responsive to Program Announcement PA-09- 113, Manufacturing Processes of Medical, Dental and Biological Technologies . This PA solicits work on technology for the manufacture of implantable devices and materials, prosthetic… More

Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$2,947,501.00
Agency:
HHS
Principal Investigator:
Shannon L. Dahl – 919-597-6625
Abstract:
DESCRIPTION (provided by applicant): This Phase IIB SBIR application is responsive to NHLBI RFA HL-13-016, NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood and Sleep Disorders and Diseases (R44) . This RFA solicits work on basic,… More